The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study
Open accessAbstract
BACKGROUND: Prescription opioid use is highly associated with risk of opioid-related death, with 1 of every 550 chronic opioid users dying within approximately 2.5 years of their first opioid prescription. Although gabapentin is widely perceived as safe, drug-induced respiratory depression has been described when gabapentin is used alone or in combination with other medications. Because gabapentin and opioids are both commonly prescribed for pain, the likelihood of co-prescription is high. However, no published studies have examined whether concomitant gabapentin therapy is associated with an increased risk of accidental opioid-related death in patients receiving opioids. The objective of this study was to investigate whether co-prescription of opioids and gabapentin is associated with an increased risk of accidental opioid-related mortality. METHODS AND FINDINGS: We conducted a population-based nested case-control study among opioid users who were residents of Ontario, Canada, between August 1, 1997, and December 31, 2013, using administrative databases. Cases, defined as opioid users who died of an opioid-related cause, were matched with up to 4 controls who also used opioids on age, sex, year of index date, history of chronic kidney disease, and a disease risk index. After matching, we included 1,256 cases and 4,619 controls. The primary exposure was concomitant gabapentin use in the 120 days preceding the index date. A secondary analysis characterized gabapentin dose as low (<900 mg daily), moderate (900 to 1,799 mg daily), or high (≥1,800 mg daily). A sensitivity analysis examined the effect of concomitant nonsteroidal anti-inflammatory drug (NSAID) use in the preceding 120 days. Overall, 12.3% of cases (155 of 1,256) and 6.8% of controls (313 of 4,619) were prescribed gabapentin in the prior 120 days. After multivariable adjustment, co-prescription of opioids and gabapentin was associated with a significantly increased odds of opioid-related death (odds ratio [OR] 1.99, 95% CI 1.61 to 2.47, p < 0.001; adjusted OR [aOR] 1.49, 95% CI 1.18 to 1.88, p < 0.001) compared to opioid prescription alone. In the dose-response analysis, moderate-dose (OR 2.05, 95% CI 1.46 to 2.87, p < 0.001; aOR 1.56, 95% CI 1.06 to 2.28, p = 0.024) and high-dose (OR 2.20, 95% CI 1.58 to 3.08, p < 0.001; aOR 1.58, 95% CI 1.09 to 2.27, p = 0.015) gabapentin use was associated with a nearly 60% increase in the odds of opioid-related death relative to no concomitant gabapentin use. As expected, we found no significant association between co-prescription of opioids and NSAIDs and opioid-related death (OR 1.11, 95% CI 0.98 to 1.27, p = 0.113; aOR 1.14, 95% CI 0.98 to 1.32, p = 0.083). In an exploratory analysis of patients at risk of combined opioid and gabapentin use, we found that 46.0% (45,173 of 98,288) of gabapentin users in calendar year 2013 received at least 1 concomitant prescription for an opioid. This study was limited to individuals eligible for public drug coverage in Ontario, we were only able to identify prescriptions reimbursed by the government and dispensed from retail pharmacies, and information on indication for gabapentin use was not available. Furthermore, as with all observational studies, confounding due to unmeasured variables is a potential source of bias. CONCLUSIONS: In this study we found that among patients receiving prescription opioids, concomitant treatment with gabapentin was associated with a substantial increase in the risk of opioid-related death. Clinicians should consider carefully whether to continue prescribing this combination of products and, when the combination is deemed necessary, should closely monitor their patients and adjust opioid dose accordingly. Future research should investigate whether a similar interaction exists between pregabalin and opioids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749
Hux, J. E., Ivis, F., Flintoft, V., & Bica, A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.512 · Cited by 1,290
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690
Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding
Mamdani, M., Sykora, K., Li, P., Normand, S.-L. T., Streiner, D. L., Austin, P. C., Rochon, P. A., & Anderson, G. M. (2005) · BMJ · doi:10.1136/bmj.330.7497.960 · Cited by 646
Self-citationOpioid Dose and Drug-Related Mortality in Patients With Nonmalignant Pain
Gomes, T., Mamdani, M. M., Dhalla, I. A., Paterson, J. M., & Juurlink, D. N. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.117 · Cited by 638
Self-citationPark, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579
Dhalla, I. A., Mamdani, M. M., Sivilotti, M. L. A., Kopp, A., Qureshi, O., & Juurlink, D. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090784 · Cited by 438
Self-citationGabapentin misuse, abuse and diversion: A systematic review
Smith, R. V., Havens, J. R., & Walsh, S. L. (2016) · Addiction · doi:10.1111/add.13324 · Cited by 378
Gabapentin Enhances the Analgesic Effect of Morphine in Healthy Volunteers
Eckhardt, K., Ammon, S., Hofmann, U., Riebe, A., Gugeler, N., & Mikus, G. (2000) · Anesthesia & Analgesia · doi:10.1097/00000539-200007000-00035 · Cited by 286
Clinical pharmacokinetics of gabapentin.
McLean, M. J. (1994) · PubMed · Cited by 262
Cited by
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Global patterns of opioid use and dependence: harms to populations, interventions, and future action
Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B. D. L., Bruneau, J., Altice, F. L., Henderson, G., Rahimi-Movaghar, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32229-9 · Cited by 832
Verret, M., Lauzier, F., Zarychanski, R., Perron, C., Savard, X., Pinard, A.-M., Leblanc, G., Cossi, M.-J., Neveu, X., Turgeon, A. F., et al. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003428 · Cited by 457
Moisset, X., Bouhassira, D., Avez Couturier, J., Alchaar, H., Conradi, S., Delmotte, M. H., Lanteri-Minet, M., Lefaucheur, J. P., Mick, G., Piano, V., et al. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.361 · Cited by 450
Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline
Paice, J. A., Bohlke, K., Barton, D., Craig, D. S., El-Jawahri, A., Hershman, D. L., Kong, L. R., Kurita, G. P., LeBlanc, T. W., Mercadante, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02198 · Cited by 304
Metadata
- Authors
- Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., & van den Brink, W.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-10-03
- Volume
- 14
- Issue
- 10
- Pages
- e1002396
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2760847338
- Cited by
- 524
- References
- 21
- FWCI
- 41.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. https://app.cochat.ai/papers/10.1371/journal.pmed.1002396
- The paper
- Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., & van den Brink, W. (2017). Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.